NCT01644617View on ClinicalTrials.gov

A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Rhinitis, Allergic, PerennialRhinitis, Allergic, Nonseasonal
Interventions
DRUG

Placebo

Placebo rapidly dissolving tablets administered sublingually once daily

DRUG

MK-8237 6 DU

MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily

DRUG

MK-8237 12 DU

MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

ALK-Abelló A/S

INDUSTRY

NCT01644617 - A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627) | Biotech Hunter | Biotech Hunter